< Back to search
Filter
1

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Location: Portland ME, South Portland ME, Boston MA,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase3, Recruiting

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 0+

Code: NCT04984551

Phase2, Recruiting

Improving Comprehensive Care of Cancer Patients

for
Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 18+

Code: NCT05323409

Recruiting

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06967610

Phase2, Recruiting

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

for
Disease/Condition Name Cancer-related Cognitive Dysfunction,
Location: Rochester NY
Sponsor: University of Rochester NCORP Research Base

Sex: All

Age: 18+

Code: NCT07638007

Recruiting

Interested in new lymphoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Global Trial in APG2575 for Patients With CLL/SLL

for
CLL/SLL
Location: Halifax, Boston MA, Greenville NC, Richmond VA,
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18 - 70+

Code: NCT06104566

Phase3, Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for
CLL, Chronic Lymphocytic Leukemia
Location: Shirley NY, Westbury NY, New York NY, Greenfield Park,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06846671

Phase3, Recruiting

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

for
Recurrent Glioblastoma, IDH-Wildtype,
Location: Chicago IL
Sponsor: Northwestern University

Sex: All

Age: 18+

Code: NCT06410248

Phase1, Recruiting

Pharmacogenetic Determinants Of Treatment Response In Children

for
All Malignancies,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0+

Code: NCT00730678

Recruiting

Evaluation of Patients With HAM/TSP

for
HTLV-I Infection, Tropical Spastic Paraparesis
Location: Bethesda MD
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Sex: All

Age: 18 - 70+

Code: NCT00001778

Recruiting

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06815003

Phase2, Recruiting

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

for
aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia,
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06904482

Phase2, Recruiting

Increasing Knowledge and Interest in Cancer Clinical Trials

for
Hematopoietic and Lymphoid Cell Neoplasm,
Location: Detroit MI
Sponsor: Hayley Thompson

Sex: All

Age: 21+

Code: NCT06501040

Recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

for
Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07257055

Phase2, Recruiting

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

for
Acute Lymphocytic Leukemia (ALL)
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07053059

Phase2, Recruiting

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

for
EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis,
Location: Bethesda MD
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18 - 29

Code: NCT06908096

Phase1, Recruiting

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

for
Waldenstrom Macroglobulinemia
Location: Boston MA, Dallas TX, Denver CO
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06561347

Phase2, Recruiting

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

for
Healthy Subject, Hematologic and Lymphocytic Disorder,
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 19+

Code: NCT03207854

Recruiting

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

for
Juvenile Myelomonocytic Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 0 - 70+

Code: NCT03326921

Phase1, Recruiting

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Location: St. John's, Bangor ME, Scarborough ME, Providence RI,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 30

Code: NCT04546399

Phase2, Recruiting